Drug Information

Drug (ID: DG01787) and It's Reported Resistant Information

• Name: Carbon tetrachloride
• Synonyms: CARBON TETRACHLORIDE; Tetrachloromethane; 56-23-5; Perchloromethane; Tetrasol; Vermoestricid; Benzinoform; Necatorine; Tetrafinol; Carbona; Univerm; Methane, tetrachloro-; Carbon tet; Methane tetrachloride; Flukoids; Necatorina; Tetraform; Carbon chloride; Tetrachlormethan; Tetrachloormetaan; Tetrachlorocarbon; Freon 10; carbontetrachloride; CCl4; Tetraclorometano; Tetrachloorkoolstof; Czterochlorek wegla; Halon 1040; Carbon chloride (CCl4); Chlorid uhlicity; R 10 (Refrigerant); Tetrachlorure de carbone; Tetracloruro di carbonio; Refrigerant R10; tetrachloro-methane; RCRA waste number U211; Tetrachlorkohlenstoff, tetra; HSDB 53; ENT 4,705; Thawpit; Tetra; R 10; UNII-CL2T97X0V0; ENT 27164; NSC 97063; CHEBI:27385; Halon 104; CL2T97X0V0; MFCD00000785; NCGC00091016-02; DSSTox_CID_250; DSSTox_RID_75464; DSSTox_GSID_20250; Caswell No. 164; CC m0; Chlorid uhlicity [Czech]; Tetrachlormethan [German]; Tetraclorometano [Italian]; Tetrachloorkoolstof [Dutch]; CAS-56-23-5; Carbon tetrachloride, analytical standard; Czterochlorek wegla [Polish]; CCRIS 123; Kohlenstofftetrachlorid; Carbon tetrachloride [BSI:ISO]; Tetrachlorure de carbone [French]; Tetracloruro di carbonio [Italian]; EINECS 200-262-8; UN1846; Tetrachlorkohlenstoff, tetra [German]; RCRA waste no. U211; EPA Pesticide Chemical Code 016501; Tetrachlorure de carbone [ISO-French]; Benzenoform; Katharin; Seretin; perchorormethane; tetrachorocarbon; tetrachlormethane; AI3-04705; Carbon chloride ; tetrachloridocarbon; carbon tetracloride; tetra-chloromethane; tetrachloro methane; carbon tetrachioride; carbon-tetrachloride; F10; Tetrachlorkohlenstoff; carbon tetra-chloride; Cl4C; carbon tetra- chloride; Tetrachloromethane, 9CI; WLN: GXGGG; Carbon tetrachloride [NF]; EC 200-262-8; Carbon tetrachloride, 99%; CHEMBL44814; SCHEMBL2466909; DTXSID8020250; NSC97063; ZINC8214515; Tox21_111057; Tox21_200039; BDBM50237610; NSC-97063; AKOS015903411; UN 1846; NCGC00091016-01; NCGC00091016-03; NCGC00091016-04; NCGC00257593-01; Carbon tetrachloride (1mg/ml in methanol); Carbon tetrachloride [UN1846] [Poison]; Carbon tetrachloride, anhydrous, >=99.5%; Carbon tetrachloride, for HPLC, >=99.9%; Carbon tetrachloride, reagent grade, 99.9%; Tetrachloromethane 100 microg/mL in Methanol; C07561; Carbon tetrachloride 100 microg/mL in Methanol; Carbon tetrachloride 5000 microg/mL in Methanol; L023972; Q225045; BRD-K24169676-001-01-1; F0001-1467
• Indication:
  In total 1 Indication(s)
  Influenza virus infection [ICD-11: 1E30-1E32]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Liver diseases [ICD-11: DB90-DB9Z]; [2]
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Hepatic fibrosis/cirrhosis [ICD-11: DB93]; [1]
• Target: .; NOUNIPROTAC; [1]
• IsoSMILES: C(Cl)(Cl)(Cl)Cl
• InChI: InChI=1S/CCl4/c2-1(3,4)5
• InChIKey: VZGDMQKNWNREIO-UHFFFAOYSA-N
• PubChem CID: 5943
• ChEBI ID: CHEBI:27385
• TTD Drug ID: D0L9PX

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-13: Digestive system diseases

Liver diseases [ICD-11: DB90-DB9Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: COX2 (COX2) [2]

• Molecule Alteration: .
• Resistant Disease: Liver diseases [ICD-11: DB90-DB9Z]
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Male BALB/c nude mice model; Mus musculus
• Mechanism Description: Expression of COX-2 and LncRNA-COX-2 increased with the progression of liver fibrosis. LncRNA-COX-2 may potentially be considered as a novel therapeutic target for liver fibrosis.

Hepatic fibrosis/cirrhosis [ICD-11: DB93]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Growth arrest specific 5 (GAS5) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Hepatic fibrosis [ICD-11: DB93.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: HSC cells; N.A.; .; N.A.
• In Vivo Model: Rat hepatic fibrosis model; Rattus norvegicus
• Experiment for Molecule Alteration: qRT-PCR; Western bloting analysis; Dual luciferase assay; RNA pull down assay
• Mechanism Description: LncRNA GAS5/miR-23a may bring molecular targets for hepatic fibrosis therapy.LncRNA GAS5 restrains CCl4-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathway.

References

• Ref 1: lncRNA GAS5 restrains CCl(4)-induced hepatic fibrosis by targeting miR-23a through the PTEN/PI3K/Akt signaling pathwayAm J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G539-G550. doi: 10.1152/ajpgi.00249.2018. Epub 2019 Feb 8.
• Ref 2: Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachlorideMol Med Rep. 2017 Apr;15(4):1507-1512. doi: 10.3892/mmr.2017.6161. Epub 2017 Feb 2.